U.S. Markets closed
  • S&P 500

    4,274.04
    -31.16 (-0.72%)
     
  • Dow 30

    33,980.32
    -171.69 (-0.50%)
     
  • Nasdaq

    12,938.12
    -164.43 (-1.25%)
     
  • Russell 2000

    1,987.31
    -33.22 (-1.64%)
     
  • Crude Oil

    87.98
    +1.45 (+1.68%)
     
  • Gold

    1,777.70
    -12.00 (-0.67%)
     
  • Silver

    19.75
    -0.33 (-1.67%)
     
  • EUR/USD

    1.0181
    +0.0010 (+0.1018%)
     
  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     
  • Vix

    19.90
    +0.21 (+1.07%)
     
  • GBP/USD

    1.2052
    -0.0043 (-0.3519%)
     
  • USD/JPY

    135.0830
    +0.8680 (+0.6467%)
     
  • BTC-USD

    23,398.38
    -533.80 (-2.23%)
     
  • CMC Crypto 200

    557.30
    -15.52 (-2.71%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Soligenix Inc (NASDAQ: SNGXannounced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) had been published in the Journal of the American Medical Association (JAMA) Dermatology.

  • "The peer-reviewed publication of these data in JAMA Dermatology is a testament and further validation to the importance of the findings for the scientific and CTCL disease communities," stated Ellen Kim, the Lead Principal Investigator for Phase 3 FLASH study.

  • Also Read: Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants

  • The published findings demonstrate that HyBryte statistically significantly reduced lesion size, with the treatment response further improving over successive 6-week treatment cycles.

  • After the first 6-week treatment window, 16% of patients responded. This response rate continued to increase significantly to 49% through 18 weeks of treatment versus patients with 6-week hypericin or placebo.

  • Throughout the study, HyBryte was safe and well-tolerated. HyBryte was observed to perform similarly against both patch and thicker plaque lesions characteristic of CTCL.

  • Price Action: SNGX shares are up 10.63% at $0.80 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.